Study to Evaluate the Safety & Efficacy of PF-06939926 for the Treatment

Status Active, not recruiting

Clinical Trial Summary

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.

Clinical Trial Description

The study will assess the efficacy of PF-06939926 gene therapy on ambulatory function while also monitoring its safety. Approximately 99 boys with DMD will be enrolled and randomly assigned to one of two groups: approximately two thirds will be in Cohort 1 and receive gene therapy at the start of the study; approximately one third will be in Cohort 2 and receive placebo at the start of the study and receive gene therapy after one year, as long as it remains safe to do so. The treatment (PF-06939926 gene therapy or placebo) will be given as an intravenous infusion lasting up to 2 hours. The study includes boys who are at least 4 years old and less than 8 years old (including 7 year olds up until their 8th birthday). All boys will need to be on a daily dose of glucocorticoids (prednisone, prednisolone, or deflazacort) for at least 3 months prior to enrolling and to stay on daily glucocorticoids for the first 2 years of the study. All boys will need to be negative for neutralizing antibodies against AAV9, as measured by the test done for the study as part of screening. The primary outcome of the study will be assessed at 52 weeks. All participants will be followed in the study for 5 years after treatment with gene therapy. The study medication, all medical tests associated with the study, and the visits to the study sites are free of charge. Participants will also be supported for travel costs associated with study visits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04281485
Study type	Interventional
Source	Pfizer
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	November 5, 2020
Completion date	April 19, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05575648` - Dual Task in Duchenne Muscular Dystrophy	N/A
Terminated	`NCT03907072` - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2/Phase 3
Not yet recruiting	`NCT06450639` - An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT04335942` - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor	N/A
Active, not recruiting	`NCT04906460` - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)	Phase 1/Phase 2
Active, not recruiting	`NCT02500381` - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 3
Enrolling by invitation	`NCT05967351` - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study	Phase 3
Recruiting	`NCT03067831` - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy	Phase 1/Phase 2
Recruiting	`NCT01834040` - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy	Phase 1/Phase 2
Completed	`NCT02246478` - A Study of TAS-205 for Duchenne Muscular Dystrophy	Phase 1
Active, not recruiting	`NCT01772043` - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping	N/A
Terminated	`NCT01168908` - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2
Completed	`NCT00758225` - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)	Phase 2
Completed	`NCT03680365` - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting	`NCT03513367` - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting	`NCT05712447` - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting	`NCT01484678` - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed	`NCT03319030` - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated	`NCT01753804` - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.	N/A
Completed	`NCT02530905` - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms